Enlivex Therapeutics Ltd.

Tel Aviv Stock Exchange ENLV.TA

Enlivex Therapeutics Ltd. EBITDA Margin for the year ending December 31, 2023

Enlivex Therapeutics Ltd. EBITDA Margin is NA for the year ending December 31, 2023. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
SV Wall Street
Tel Aviv Stock Exchange: ENLV.TA

Enlivex Therapeutics Ltd.

CEO Dr. Oren Hershkovitz Ph.D.
IPO Date July 22, 2019
Location Israel
Headquarters 14 Einstein Street
Employees 77
Sector Healthcare
Industries
Biotechnology 3D Printing Clinical Trials Pharmaceuticals Vaccines
Description

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

StockViz Staff

February 6, 2025

Any question? Send us an email